Opko Health, Inc.

Good day and welcome to the Opco Health First Quarter 2026 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the Star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press Star then 1 on your touchtone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead.

Thank you, Operator, and good afternoon. This is Yvonne Briggs with Alliance Advisors IR. Thank you all for joining today's call to discuss Opco Health financial results for the first quarter of 2026. I'd like to remind you that any statements made during this call by management other than statements of historical fact will be considered forward-looking, and as such, are subject to risks and uncertainties that can materially affect the company's results. Those forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2025. Furthermore, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, April 28, 2026. Except as required by law, OPCO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Regarding the format of today's call, Dr. Philip Frost, Chairman and Chief Executive Officer, will provide opening remarks. Dr. Elias Zerhouni, Vice Chairman and President, will then provide an overview of OPCO's therapeutic segment, as well as bioreference health. After that, Adam Logel, OPCO's CFO, will review the company's first quarter financial results and discuss OPCO's financial outlook, and then we'll open the call to questions. Now I'd like to turn the call over to Dr. Frost.

Thank you for joining us today. During the first quarter, we made meaningful progress with our strategic initiatives, with particular emphasis on advancing our MODX product development pipeline. MODX now has five programs in the clinic, spanning vaccines, oncology, and immunology, all with the potential to be first and best in class in their therapeutic areas. Days after the close of the first quarter, we dosed our first subjects in the Phase I clinical trial of MDX2301, our BARDA-funded multispecific antibody for the prevention of COVID in high-risk populations. Shortly thereafter, we announced the dosing of the first patient in the Phase I trial to evaluate MDX2003, a tetraspecific T-cell engager, in patients with relapsed or refractory B-cell lymphoma. We also continue to advance our other oncology candidates in clinical development, MDX2001, a tetraspecific T-cell engager targeting solid tumors, and MDX2004, a multispecific immune rejuvenator. Over the course of this year, we expect MODX to achieve a number of clinical and partnership milestones as these programs progress and, in the case of our EBV vaccine, approach later stage development with our partner, Merck. Our collaboration with Regeneron is progressing well as we align their extensive antibody binder library with our multi-specific engineering platform across various indications in metabolism, oncology, and immunology. This collaboration is another example of strategic partnerships that are a good source of non-dilutive capital to support our R&D efforts. The potential total value of the Regeneron collaboration exceeds $1 billion in milestones plus future royalties. In our diagnostics business, Q1 reflects our second full quarter with the new bioreference footprint, following our oncology divestiture. We're now centered on our core regional clinical laboratory operations in New York and New Jersey, our correctional health business, and our national specialty urology testing franchise, anchored by the 4K score test. We continue to streamline our infrastructure and cost base to achieve profitable growth from this segment. We close the quarter with a solid cash balance. This reflects past asset sales, continued R&D support from our partners, and contributions from our international pharmaceutical operations. This financial strength enables us to fund our R&D portfolio at a meaningful level and to return capital to shareholders through our stock repurchase program. With that overview, I'll turn the call over to Elias.